Correlation Study of Chronic Nonbacterial Prostatitis with the Levels of COX-2 and PGE2 in Prostatic Secretion

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2014 Jun 9

PMID 24908280

Citations 4

Authors

Zhi Yuan

Xiaoli Liu

Wentao Deng

Xiaodong Lai

Zaichun Yan

Ruqiang Zheng

Affiliations

Soon will be listed here.

Abstract

Objective: The prostatitis syndrome is a multifactorial condition of largely unknown etiology. This study is to analyze the relationship between cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) with the chronic nonbacterial prostatitis (CNBP).

Methods: A total of 172 CNBP patients and 151 healthy males were recruited as CNBP and control group, respectively. The prostatic fluid was collected and tested by pre- and post-massage test. White blood cell (WBC) number was counted, and the contents of COX-2 and PGE2 were determined by double antibody-based sandwich enzyme-linked immuno-sorbent assay. The pain and discomfort of each patient were scored according to the National Institutes of Health chronic prostatitis symptom index.

Results: Compared with the control group, CNBP group displayed significantly higher WBC count, COX-2 level, and PGE2 level. Contents of COX-2 and PGE2 in prostatic secretion of CNBP group were positively correlated with pain scores (r = 0.855 and 0.675, respectively, P < 0.01) and total symptom scores (r = 0.674 and 0.566, respectively, P < 0.01). A significantly positive correlation between COX-2 and PGE2 levels was also discovered (r = 0.493, P < 0.05). The WBC number was not obviously correlated with the accumulations of COX-2 and PGE2 or the clinic symptoms of CNBP.

Conclusion: Increase in PGE2 concentration caused by activated COX-2 pathway may contribute to the pain or discomfort symptom of the CNBP patients. Our results indicate that selective COX-2 inhibitors have application prospect in CNBP treatment.

Citing Articles

Cannabidiol Alleviates Chronic Prostatitis and Chronic Pelvic Pain Syndrome CB2 Receptor Activation and TRPV1 Desensitization.

Piao J, Kim S, Shin D, Lee H, Jeon K, Tian W World J Mens Health. 2024; 43(1):228-238.

PMID: 38449457 PMC: 11704163. DOI: 10.5534/wjmh.230352.

Effect of electroacupuncture on inflammatory signal expression in local tissues of rats with chronic pelvic pain syndrome based on purinergic 2X7 receptor/NOD-like receptor pyrin domain-containing 3 signal pathway.

Chang X, Na L, Xiaoling W, Xingye D, Zhiwen Y, Qianhui S J Tradit Chin Med. 2022; 42(6):965-971.

PMID: 36378055 PMC: 9924754. DOI: 10.19852/j.cnki.jtcm.20220928.003.

Mechanism of Acupuncture and Moxibustion on Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Narrative Review of Animal Studies.

Wu X, Cheng K, Xu C, Liu S, Sun Q, Yang Z Pain Res Manag. 2021; 2021:2678242.

PMID: 34925658 PMC: 8674039. DOI: 10.1155/2021/2678242.

Therapeutic effects of Qian-Yu decoction and its three extracts on carrageenan-induced chronic prostatitis/chronic pelvic pain syndrome in rats.

Zhang K, Zeng X, Chen Y, Zhao R, Wang H, Wu J BMC Complement Altern Med. 2017; 17(1):75.

PMID: 28122556 PMC: 5264336. DOI: 10.1186/s12906-016-1553-7.

References

Nickel J . The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. Tech Urol. 1997; 3(1):38-43. View

Kurumbail R, Kiefer J, Marnett L . Cyclooxygenase enzymes: catalysis and inhibition. Curr Opin Struct Biol. 2001; 11(6):752-60. DOI: 10.1016/s0959-440x(01)00277-9. View

Sutcliffe S, Grubb Iii R, Platz E, Ragard L, Riley T, Kazin S . Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int. 2012; 110(7):1050-9. PMC: 3382045. DOI: 10.1111/j.1464-410X.2011.10867.x. View

Zhao W, Zhang Z, Li X, Yu D, Rui X, Li G . Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Braz J Med Biol Res. 2009; 42(10):963-7. DOI: 10.1590/s0100-879x2009005000021. View

Nickel J, Pontari M, Moon T, Gittelman M, Malek G, Farrington J . A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol. 2003; 169(4):1401-5. DOI: 10.1097/01.ju.0000054983.45096.16. View

Sharma-Walia N, Paul A, Bottero V, Sadagopan S, Veettil M, Kerur N . Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog. 2010; 6(2):e1000777. PMC: 2820536. DOI: 10.1371/journal.ppat.1000777. View

Cohen J, Fagin A, Hariton E, Niska J, Pierce M, Kuriyama A . Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis. PLoS One. 2012; 7(8):e41941. PMC: 3411608. DOI: 10.1371/journal.pone.0041941. View

Schaeffer A, Datta N, Fowler Jr J, Krieger J, Litwin M, Nadler R . Overview summary statement. Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Urology. 2003; 60(6 Suppl):1-4. DOI: 10.1016/s0090-4295(02)01979-9. View

Krieger J, Lee S, Jeon J, Cheah P, Liong M, Riley D . Epidemiology of prostatitis. Int J Antimicrob Agents. 2008; 31 Suppl 1:S85-90. PMC: 2292121. DOI: 10.1016/j.ijantimicag.2007.08.028. View

10.

Hawkey C . COX-2 inhibitors. Lancet. 1999; 353(9149):307-14. DOI: 10.1016/s0140-6736(98)12154-2. View

11.

Propert K, Litwin M, Wang Y, Alexander R, Calhoun E, Nickel J . Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res. 2006; 15(2):299-305. DOI: 10.1007/s11136-005-1317-1. View

12.

Bachmann A, Schurch L, Ruszat R, Wyler S, Seifert H, Muller A . Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol. 2005; 48(6):965-71. DOI: 10.1016/j.eururo.2005.07.001. View

13.

Ponniah S, Arah I, Alexander R . PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate. 2000; 44(1):49-54. DOI: 10.1002/1097-0045(20000615)44:1<49::aid-pros7>3.0.co;2-7. View

14.

Kalinski P . Regulation of immune responses by prostaglandin E2. J Immunol. 2011; 188(1):21-8. PMC: 3249979. DOI: 10.4049/jimmunol.1101029. View

15.

Hennenfent B, Lazarte A, Feliciano Jr A . Repetitive prostatic massage and drug therapy as an alternative to transurethral resection of the prostate. MedGenMed. 2007; 8(4):19. PMC: 1868377. View

16.

Alexander R, Ponniah S, Hasday J, Hebel J . Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology. 1998; 52(5):744-9. DOI: 10.1016/s0090-4295(98)00390-2. View

17.

Park S, Lee S, Chung Y, Park K, Mah S, Hong S . Warm sitz bath: are there benefits after transurethral resection of the prostate?. Korean J Urol. 2010; 51(11):763-6. PMC: 2991573. DOI: 10.4111/kju.2010.51.11.763. View

18.

Schaeffer A, Wu S, Tennenberg A, Kahn J . Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol. 2005; 174(1):161-4. DOI: 10.1097/01.ju.0000162017.24965.2b. View

19.

Nickel J, Krieger J, McNaughton-Collins M, Anderson R, Pontari M, Shoskes D . Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med. 2008; 359(25):2663-73. PMC: 2815340. DOI: 10.1056/NEJMoa0803240. View

20.

Aid S, Bosetti F . Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. Biochimie. 2010; 93(1):46-51. PMC: 3008299. DOI: 10.1016/j.biochi.2010.09.009. View